Fund Evaluator:
Stt Strt® SPDR® S&P®HlthCrSvcsETF (XHS)
Follow This Fund
Equity
Global Asset Class
Sector Equity
Fund Group
Health
Category
$61.400
NAV (as of Oct 07)
$0.00
Minimum Initial
0.35% A
Expense Ratio
$204 Mil
Assets
Open
Status
na
12b-1 Fee
0.20%
TTM Yield
0.00%
Max Load
44%
Portfolio Turnover
Best Performing in Health Over the Last Year
| 62.8% | Fidelity Advisor Biotechnology Z (FIJYX) |
| 62.6% | Fidelity Advisor Biotechnology I (FBTIX) |
| 56.2% | Eventide Healthcare & Life Sciences N (ETNHX) |
| 53.5% | Fidelity Select Biotechnology (FBIOX) |
| 49.5% | Fidelity Select Pharmaceuticals Port (FPHAX) |
Data as of 7/31/2026
0.5% C
1-Mo Return
20.7% A
3-Mo Return
24.2% A
YTD Return
47.9% B
1-Yr Return
12.5% B
3-Yr Return
3.7% C
5-Yr Return
1.06 D
Category Risk Index
1.74
Total Risk Index
Fund Details
Fund Family
State Street Investment Management
Inception Date
9/28/2011
Share Class Type
Equity Investment Style
Small-Cap
Blend
Bond Investment Style
na
Socially Responsible Fund
No
Index Fund
Yes
Benchmark Index
S&P 500 (TR) (1970): 100%
Additional Fund Details
Stt Strt® SPDR® S&P®HlthCrSvcsETF Overview
XHS Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| XHS Return (NAV) | 0.5% | 20.7% | 47.9% | 12.5% | 3.7% | 9.0% |
| XHS Grade | C | A | B | B | C | C |
| +/- Category | 0.9% | 10.0% | 14.0% | 1.8% | -1.3% | -0.3% |
| Health Avg | -0.4% | 10.7% | 33.9% | 10.7% | 5.0% | 9.3% |
| XHS Tax Cost Ratio | na | na | 0.1% | 0.1% | 0.1% | 0.2% |
XHS Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| XHS Return (NAV) | 24.2% | 18.7% | 1.9% | 5.1% | -19.9% | 9.8% | 33.3% | 18.7% | 2.6% | 17.1% | -8.2% |
| XHS Grade | A | D | C | B | D | C | A | F | B | D | C |
| +/- Category | 17.1% | -1.9% | -0.7% | -0.4% | -10.5% | 1.1% | 8.9% | -9.7% | 2.3% | -6.3% | 2.7% |
| Health Avg | 7.1% | 20.6% | 2.5% | 5.6% | -9.4% | 8.7% | 24.5% | 28.4% | 0.4% | 23.4% | -10.9% |
| Risk Measures | |
| Standard Deviation: | 21.4% |
| Total Risk Index: | 1.74 - High |
| Category Risk Index: | 1.06 - Above Average |
| Category Risk Grade: | D (64% Rank) |
| Beta: | 0.98 |
| R-Squared: | 34% |
| Leveraged Fund: | No |
| Inverse Fund: | No |
| Portfolio Characteristics | |
| Equity Investment Style: | Small-Cap Blend |
| Bond Investment Style: | na |
| Yield: | 0.2% |
| Dividend Distribution: | Quarterly |
| Cap Gains Distribution: | Annually |
| Total Assets: | $204 Mil |
| Fund Total Assets: | $ 204 Mil |
| Share Class Type: | |
| Portfolio Turnover: | 44% |
Management Team
| Number of Managers: 3 | |||
| Longest Tenure: 11.8 years | |||
| Average Tenure: 6.8 years | |||
| Managers (Year): Schneider Karl (2014), Donofrio Raymond (2018), Rabinovich Emiliano (2025) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 61 |
| % in Top 10 Holdings: | 21.2% |
| Fund is Non-Diversified: | No |
| % in Foreign Issues: | 0.0% |
Portfolio Allocation |
|
| Domestic Stock: | 100.0% |
| Foreign Stock: | 0.0% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 0.1% |
Purchase Information
| Fund Family: | State Street Investment Management |
| Phone Number: | 866-787-2257 |
| Website: | www.spdrs.com |
| Status: | Open |
| Inception Date: | September 28, 2011 |
| Min. Initial Purchase: | $ 0 |
| Min. Initial IRA Purchase: | $ 0 |
| True No-Load: | Yes |
| Front Load Maximum: | 0.00% |
| Deferred Charge Maximum: | 0.00% |
| Redemption Charge Maximum: | 0.00% |
| 12b-1 Fee: | na |
Expenses and Fees | |
| Expense Ratio (%): | 0.35% ( Rating : Below Avg ) |
| Category Average Expense Ratio (%): | 1.21% |
| Share Class: | Stt Strt® SPDR® S&P®HlthCrSvcsETF |
| Min. Subsequent Purchase: | $ 0 |
| Min. Subsequent IRA Purchase: | $ 0 |
Copyright 2026 American Association of Individual Investors and Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.